Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study

ClinicalTrials.gov ID: NCT02158546

Public ClinicalTrials.gov record NCT02158546. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the efficacy and safety of ALKS 5461.

Study identification

NCT ID
NCT02158546
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
447 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2014
Primary completion
Nov 30, 2015
Completion
Nov 30, 2015
Last update posted
Jun 24, 2019

2014 – 2015

United States locations

U.S. sites
50
U.S. states
23
U.S. cities
48
Facility City State ZIP Site status
Alkermes Investigational Site Little Rock Arkansas 72211
Alkermes Investigational Site Bellflower California 90706
Alkermes Investigational Site Beverly Hills California 90210
Alkermes Investigational Site Glendale California 91206
Alkermes Investigational Site Los Alamitos California 90720
Alkermes Investigational Site Orange California 92868
Alkermes Investigational Site Redlands California 92374
Alkermes Investigational Site Temecula California 92591
Alkermes Investigational Site Washington D.C. District of Columbia 20016
Alkermes Investigational Site Hallandale Florida 33009
Alkermes Investigational Site Hialeah Florida 33016
Alkermes Investigational Site Jacksonville Florida 32256
Alkermes Investigational Site Leesburg Florida 34748
Alkermes Investigational Site Maitland Florida 32751
Alkermes Investigational Site Tampa Florida 33613
Alkermes Investigational Site Atlanta Georgia 30331
Alkermes Investigational Site Chicago Illinois 60634
Alkermes Investigational Site Oak Brook Illinois 60523
Alkermes Investigational Site Vernon Hills Illinois 60061
Alkermes Investigational Site Indianapolis Indiana 46260
Alkermes Investigational Site Lafayette Indiana 47905
Alkermes Investigational Site Edgewood Kentucky 41017
Alkermes Investigational Washington DC Maryland 20016
Alkermes Investigational Site Brockton Massachusetts 02301
Alkermes Investigational Site Watertown Massachusetts 02472
Alkermes Investigational Site Kansas City Missouri 64114
Alkermes Investigational Site O'Fallon Missouri 63368
Alkermes Investigational Site St Louis Missouri 63109
Alkermes Investigational Site Cherry Hill New Jersey 08002
Alkermes Investigational Site Albuquerque New Mexico 87109
Alkermes Investigational Site Jamaica New York 11432
Alkermes Investigational Site New York New York 10023
Alkermes Investigational Site Staten Island New York 10312
Alkermes Investigational Site Charlotte North Carolina 28204
Alkermes Investigational Site Beachwood Ohio 44122
Alkermes Investigational Site Cincinnati Ohio 45215
Alkermes Investigational Site Cincinnati Ohio 45227
Alkermes Investigational Site Mason Ohio 45040
Alkermes Investigational Site Middleburg Heights Ohio 44130
Alkermes Investigational Site Portland Oregon 97210
Alkermes Investigational Site Salem Oregon 97301
Alkermes Investigational Site Philadelphia Pennsylvania 19104
Alkermes Investigational Site Charleston South Carolina 29407
Alkermes Investigational Site Memphis Tennessee 38119
Alkermes Investigational Site Dallas Texas 75231
Alkermes Investigational Site Dallas Texas 75309
Alkermes Investigational Site Houston Texas 77098
Alkermes Investigational Site Sugar Land Texas 77478
Alkermes Investigational Site Bellevue Washington 98007
Alkermes Investigational Site Waukesha Wisconsin 53188

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02158546, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 24, 2019 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02158546 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →